HHS purchases IV antiviral drug to treat monkeypox
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the manufacturer expects to deliver next year. Under its contract with SIGA Technologies, HHS may still purchase additional oral and IV TPOXX, an antiviral drug approved by the Food and Drug Administration to treat smallpox and available under an investigational protocol to treat monkeypox. TPOXX is available free to states and territories through the Strategic National Stockpile, which held over 1.7 million treatment courses before the monkeypox outbreak. HHS last week declared the U.S. outbreak, which exceeds 10,000 cases, a public health emergency.
Related News Articles
Headline
There have been 1,024 confirmed cases of measles across the U.S. so far in 2025, according to the latest data from the Centers for Disease Control and…
Headline
There have been 1,001 confirmed cases of measles across the U.S. so far in 2025, according to the latest data from the Centers for Disease Control and…
Headline
Though seasonal flu activity is low or minimal across the country, 216 pediatric deaths associated with seasonal influenza virus infection have been tallied so…
Headline
The U.S. has had 935 confirmed cases of measles so far this year, according to the latest data from the Centers for Disease Control and Prevention. Cases have…
Headline
There have been 884 confirmed cases of measles nationwide so far this year, with cases reported by 29 states, according to the latest data from the…
Headline
There have been 8,064 reported cases of whooping cough in the U.S. so far this year, according to the latest data from the Centers for Disease Control and…